Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study.
Antibodies
COVID-19
Cohort-study
Coronavirus
ELISA
Pandemic
Risk behaviors
Risk factors
Surveillance
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
07 07 2022
07 07 2022
Historique:
received:
05
04
2022
accepted:
03
06
2022
entrez:
7
7
2022
pubmed:
8
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life. The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms. The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases. DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.
Sections du résumé
BACKGROUND
Considering the insufficiently controlled spread of new SARS-CoV-2 variants, partially low vaccination rates, and increased risk of a post-COVID syndrome, well-functioning, targeted intervention measures at local and national levels are urgently needed to contain the SARS-CoV-2 pandemic. Surveillance concepts (cross-sectional, cohorts, clusters) need to be carefully selected to monitor and assess incidence and prevalence at the population level. A critical methodological gap for identifying specific risks/dynamics for SARS-Cov-2 transmission and post-COVID-19-syndrome includes repetitive testing for past or present infection of a defined cohort with simultaneous assessment of symptoms, behavior, risk, and protective factors, as well as quality of life.
METHODS
The ELISA-Study is a longitudinal, prospective surveillance study with a cohort approach launched in Luebeck in April 2020. The first part comprised regular PCR testing, antibody measurements, and a recurrent App-based questionnaire for a population-based cohort of 3000 inhabitants of Luebeck. The follow-up study protocol includes self-testing for antibodies and PCR testing for a subset of the participants, focusing on studying immunity after vaccination and/or infection and post-COVID-19 symptoms.
DISCUSSION
The ELISA cohort and our follow-up study protocol will enable us to study the effects of a sharp increase of SARS-CoV-2 infections on seroprevalence of Anti-SARS-CoV-2 antibodies, post-COVID-19-symptoms, and possible medical, occupational, and behavioral risk factors. We will be able to monitor the pandemic continuously and discover potential sequelae of an infection long-term. Further examinations can be readily set up on an ad-hoc basis in the future. Our study protocol can be adapted to other regions and settings and is transferable to other infectious diseases.
TRIAL REGISTRATION
DRKS.de, German Clinical Trials Register (DRKS), Identifier: DRKS00023418 , Registered on 28 October 2020.
Identifiants
pubmed: 35799167
doi: 10.1186/s12889-022-13666-z
pii: 10.1186/s12889-022-13666-z
pmc: PMC9261226
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1305Informations de copyright
© 2022. The Author(s).
Références
Open Forum Infect Dis. 2021 Jul 27;8(8):ofab379
pubmed: 34377733
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
Lancet Infect Dis. 2021 Oct;21(10):1373-1382
pubmed: 33984263
Lancet Reg Health Eur. 2021 May;4:100098
pubmed: 33969335
Eur Respir J. 2021 Apr 8;57(4):
pubmed: 33303542
PLoS One. 2021 Oct 8;16(10):e0258255
pubmed: 34624024
Lancet Glob Health. 2021 Jul;9(7):e925-e931
pubmed: 34022148
Nat Commun. 2020 Sep 9;11(1):4507
pubmed: 32908126
Eur J Immunol. 2022 Jan;52(1):149-160
pubmed: 34695227
BMC Public Health. 2020 Jun 30;20(1):1036
pubmed: 32605549
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
BMC Public Health. 2021 Jul 2;21(1):1295
pubmed: 34215236
Viruses. 2021 Jun 10;13(6):
pubmed: 34200766
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243353
Int J Environ Res Public Health. 2021 Mar 30;18(7):
pubmed: 33808249
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358